ArticleCardiovascular drugs and therapy2026
Minimally Invasive Trans-atrial Mitral Valve Replacement Using a Balloon-expandable Transcatheter Valve in the Setting of Severe Mitral Annular Calcification.
Article in Cardiovascular drugs and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSevere mitral annular calcification (MAC) increases the complexity and risk of conventional mitral valve replacement (MVR) for patients with mitral stenosis (MS) and/or regurgitation (MR). In patients with severe concentric MAC who were not candidates for a traditional surgical approach, trans-atrial transcatheter MVR (TMVR) using a balloon-expandable transcatheter aortic valve (TAVR) is an alternative. We report our experience using this technique through a minimally invasive approach.
methodsFrom April 2017 to September 2024, twenty-five symptomatic patients with severe MS and/or MR and MAC underwent minimally invasive trans-atrial TMVR with a TAVR valve at our institution. All patients had severe concentric MAC and were deemed ineligible for conventional MVR.
resultsMean age of the patients was 74.6 ± 10.9 years and 84% (21/25) were female. Mean STS (Society of Thoracic Surgery) risk score for mortality was 9.1% ± 4.8%. Operative indication was severe MS in 11 patients (44%), severe MR in 4 (16%) and mixed MS/MR in 10 (40%). Surgical approach was via right anterior mini-thoracotomy (n=21) or robotic (n=4). Five patients had prior open cardiac surgery, and 6 had prior TAVR. Six patients (24%) were under cold fibrillatory arrest. Complications included paravalvular leak requiring re-intervention (n=1), left ventricular outflow tract obstruction (n=1) and atrio-ventricular groove disruption (n=1). There were no perioperative strokes. Average hospital length-of-stay was 7 days (IQR 6–13). Operative mortality was 16% (4/25), 76.0% (19/25) of patients survived discharge, and 1-year survival was 64.0% (16/25).
conclusionMinimally invasive trans-atrial TMVR using a TAVR valve provides a viable alternative therapy for patients with severe MAC who are not candidates for conventional MVR.
Indexed as
Identifiers
41801638What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.